<- Go home

Added to YB: 2026-09-04

Pitch date: 2026-09-02

CPH.TO [neutral]

Cipher Pharmaceuticals Inc.

-1.1%

current return

Author Info

Stocks & Stones manages the Rivemont MicroCap Fund, which has several million $ in assets. I’m here to help you avoid the pitfalls of microcap investing. Sign up for the newsletter.

Company Info

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients.

Market Cap

CAD 259.4M

Pitch Price

CAD 14.55

Price Target

N/A

Dividend

N/A

EV/EBITDA

9.37

P/E

9.09

EV/Sales

5.05

Sector

Pharmaceuticals

Category

N/A

Show full summary:
The Good, the Bad, and the Ugly (August 2026) - Cipher Pharmaceuticals Inc.

CPH.TO (earnings): Cipher Pharmaceuticals reported an underwhelming second quarter, with reduced Medicaid coverage for Natroba, its main U.S. product, apparently not well telegraphed amid near-term uncertainty. Quarterly revenue and EBITDA each fell 10%, while EPS declined 30% year over year. The shares dropped as much as 25% over the following two days.

Read full article (1 min)